CTLA4 and melanoma: However, Gao et al. analyzed the clinical data of patients who did not respond to ipilimumab and found that gene defects in the IFN-γ pathway lead to melanoma’s response to immune checkpoint inhibitors, especially anti-CTLA-4 Antibody insensitivity[110].